Objective-Experimental data imply that endostatin, a proteolytically cleaved fragment of collagen XVIII, could be involved in the development of cardiovascular disease and cancer. Prospective data concerning the relation between circulating endostatin and mortality are lacking. Accordingly, we aimed to study associations between circulating endostatin and mortality risk. Approach and Results-Serum endostatin was analyzed in 2 community-based cohorts: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; women 50%, n=931; mean age, 70 years; median follow-up, 7.9 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM; n=748; mean age, 77 years; median follow-up, 9.7 years). During follow-up, 90 participants died in PIVUS (1.28/100 person-years at risk), and 417 participants died in ULSAM (6.7/100 person-years at risk). In multivariable Cox regression models adjusted for age and established cardiovascular risk factors, 1 SD higher ln(serum endostatin level) was associated with a hazard ratio of mortality of 1.39 and 95% confidence interval, 1.26 to 1.53, on average in both cohorts. In the ULSAM cohort, serum endostatin was also associated with cardiovascular mortality (177 deaths; hazard ratio per SD of ln 
T he importance of extracellular matrix remodeling in human health and disease is currently being unraveled. Collagen XVIII is a heparan sulfate proteoglycan that is localized in most epithelial and endothelial/vascular basement membranes. 1 Proteolytic cleavage of the C-terminal domain of collagen XVIII by matrix metalloproteinases, elastases, and cathepsins L and S results in a biologically active fragment called endostatin. [2] [3] [4] [5] [6] [7] During the last decade, the role of endostatin as a potent endogenous inhibitor of angiogenesis has been well documented. 2, [8] [9] [10] This antiangiogenic action of endostatin has been suggested to be of particular importance in the inhibition of cancer cell proliferation and tumor migration. [11] [12] [13] Interestingly, elevated endostatin levels have been observed in the circulation in patients with various malignant diseases. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] In some malignancies, high endostatin levels in the circulation are associated with a worse prognosis. 15, [27] [28] [29] Experimental data also suggest that there may be a role for endostatin in the development of cardiovascular disease (CVD), [30] [31] [32] and that circulating levels of endostatin are increased in patients with prevalent CVD. [33] [34] [35] [36] [37] [38] However, till date no studies have reported associations between endostatin levels and mortality risk.
Based on previous studies suggesting a role for endostatin in the development of cancer and CVD, we hypothesized that increased circulating levels of endostatin would be associated with an increased risk of mortality. Accordingly, we investigated the association between serum levels of endostatin and the risk of total mortality in a community-based cohort of elderly men and women. As a second step, we aimed at replicating the findings in an independent cohort of elderly men. As a third step, we aimed at investigating the association between endostatin and cause-specific mortality from cancer and CVD.
Materials and Methods
Materials and methods are available in the online-only supplement.
In brief, serum endostatin was analyzed in 2 community-based cohorts of the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS; women 50%, n=931; mean age, 70 years) and the Uppsala Longitudinal Study of Adult Men (ULSAM, n=748; mean age, 77 years). 39, 40 Data on cardiovascular risk factors, inflammatory markers, current medication, medical history, and socioeconomic factors were available at baseline in both cohorts. Mortality data were collected from The Swedish Cause-of-Death register.
Results
Baseline characteristics of both cohorts are shown in Table 1 . The mean serum level of endostatin was 47±14 ng/mL in both men and women in the PIVUS cohort. During follow-up of the PIVUS study (median 7.9 years, range 0.4-9.8 years), 90 participants died (incidence rate 1.25/100 person-years at risk). During follow-up of the ULSAM cohort (median 9.7 years, range 0.3-12.9 years), 417 participants died (rate 6.7/100 person-years at risk,), of which 177 died of CVD (rate 2.8/100 person-years at risk) and 115 of cancer (incidence rate 1.8/100 person-years at risk). Incidence rates by tertiles of serum endostatin are shown in Table I in the online-only Data Supplement.
Primary Analyses in the PIVUS and ULSAM Cohorts
In both cohorts, 1 SD higher ln(serum endostatin level) was on average associated with 37% to 40% higher rate of total mortality (Figure 1 ), adjusting for age (model A), lifestyle factors (model B), and established cardiovascular risk factors (model C). In tertile models, participants in the highest tertile of serum endostatin, on average, had 61% to 70% higher mortality rate than participants in the lowest tertile ( Figure 1 , models A-C). Associations were remarkably similar in the 2 cohorts, with minimal heterogeneity (I 2 =0) between the cohorts in almost all models. Cumulative mortality in the highest tertile versus the other 2 tertiles pooled is shown for both cohorts in Figure 2 . Spline models suggested a linear increase in mortality with increasing serum endostatin level in both cohorts (Figure 3 
Secondary Analyses in the ULSAM Cohort
Risk estimates for ln(endostatin) were similar after adjustment for inflammatory markers (C-reactive protein, IL-6, serum amyloid A, 15-keto-dihydro-prostaglandin factor 2α , 
Smoking, n (%) 97 (10) 57 (8) Diabetes mellitus, n (%) 80 (9) 107 (14) Previous cardiovascular disease, n (%) 149 (16) 204 (27) Lipid-lowering treatment, n (%) 145 (16) 127 (17) Antihypertensive treatment, n (%) 284 (30) 356 (48) Leisure time physical activity, n (%) 
Cardiovascular Mortality
In continuous models, 1 SD higher ln(endostatin) was associated with 45% to 55% higher rate of cardiovascular mortality, after adjustment for age, sex, lifestyle factors, and established cardiovascular risk factors (Table 2 , models A-C). In tertile models, participants in the highest tertile of endostatin were at up to a doubled risk of cardiovascular mortality compared with those in the lowest quartile ( 
Cancer Mortality
One SD higher ln(endostatin) was associated with 24% to 35% higher cancer mortality rate (Table 2 , models A-C). In tertile models, participants in the highest tertile of endostatin were at up to a doubled risk of cancer mortality compared with participants in the lowest tertile (Table 2, 
Discussion Principal Findings
In 2 independent cohorts of elderly men and women, higher serum levels of endostatin were associated with an increased mortality risk. This association was independent of age, lifestyle factors, and cardiovascular risk factors. Moreover, higher levels of endostatin were associated with cause-specific mortality both from cancer and CVD. The association was not influenced by further adjustment for markers reflecting kidney dysfunction, systemic inflammation, angiogenic activity, or proteases that generate endostatin fragments from collagen XVIII. Our data indicate that endostatin is involved in, or a marker for, pathological processes leading to the progression of cancer and CVD, and that it may be a promising biomarker for further study. We are aware of no previous study that has reported the prospective association between circulating endostatin and the risk for mortality in the community-based setting.
Comparison With the Literature
Elevated endostatin levels have been observed in the circulation from patients with different malignant diseases 14, [16] [17] [18] [19] [20] [21] [23] [24] [25] [26] and have also been associated with the severity of disease. 15, 28 Moreover, higher endostatin levels have been reported in patients with prevalent CVD such as stroke and coronary atherosclerosis. 33, 34, 36, 37 However, prospective data on the association between circulating endostatin and adverse events are scarce and partly conflicting. In patients with non-Hodgkin lymphoma and renal carcinoma, high levels of circulating endostatin were associated with a decreased expected survival time. 27, 29 In addition, in patients with intracranial atherosclerosis, higher circulating endostatin has been shown to be an independent predictor of cerebral ischemic events, 33 and in patients with ischemic stroke, higher endostatin was associated with a poorer long-term functional outcome. 41 Interestingly, Seko et al 34 suggested that circulating levels of endostatin are increased in patients with acute myocardial infarction, but decreases during reperfusion. However, there are also some conflicting findings. In a previous small study, an inverse association between circulating endostatin and the risk of acute myocardial infarction was found in Asians and in whites, but a significant positive relation was reported in blacks. 42 
Potential Mechanisms
Although our observational data do not permit us to establish causality, there are some potential mechanisms that may explain our observations. One interpretation could be that higher circulating levels of endostatin mirror a more active extracellular matrix remodulation. Inflammatory stress [43] [44] [45] [46] [47] (inflammatory cytokines, hypoxia, ischemia) stimulates elastase, matrix-derived metalloproteinases, as well as the cathepsins, which all can induce modulation of the extracellular matrix. [48] [49] [50] This modulation has been suggested to be the main reason for the increased circulating levels of endostatin seen in malignant disease, where endostatin levels most likely reflect the breakdown of the basal membranes and tumor burden (the invasiveness of the tumor). 20 However, whether this is true for other disease states such as CVD remains to be established. Although adjustment for various factors that regulate extracellular matrix remodeling (matrix metalloproteinase 9, tissue inhibitor of metalloproteinase-1, and cathepsins L and S) or inflammatory markers did not seem to substantially influence the association between endostatin and mortality risk, we cannot rule out considerable residual confounding because the circulating levels of these factors may be poor reflectors of the specific pathophysiological processes. It is possible that the results of the present study are attributable to reverse causation, that is, that higher endostatin levels are a consequence of prevalent, possibly latent, cancer or CVD. This notion is partly supported by our subgroup analyses, indicating that the associations between endostatin and cardiovascular mortality was stronger in participants with prevalent CVD, and that the association between endostatin and cancer mortality was attenuated after excluding participants with a history of cancer at baseline or who died from cancer during the first 2 years of follow-up.
Another interpretation of our data could be that the association between endostatin and mortality reflects a systemic increased angiogenic activity initiated by an angiogenic stimulus involving extracellular matrix remodulation. VEGF, one the most potent endogenous stimulators of angiogenesis, is regulated by hypoxia, inflammatory cytokines, and oncogenes. 51, 52 Initiation of angiogenesis by VEGF involves extracellular matrix degradation. Alteration in the systemic balance of proangiogenic and antiangiogenic molecules is believed to represent an initial step in the pathology of inflammatory and malignant diseases, 53, 54 and angiogenesis has also been shown to be a key factor in the destabilization Figure 3 . Association between serum endostatin and total mortality assessed via regression splines. T indicates tertile. of atherosclerotic placques. 55 However, in secondary analyses, neither the ratio of VEGF/endostatin nor VEGF itself was associated with the outcome of the present study. Thus, our data do not support a major role for proangiogenic and antiangiogenic regulation for the present associations. However, again, we cannot rule out residual confounding because circulating VEGF may be a poor reflector of specific VEGF-activity.
It is also possible that the results may be confounded by some other causal factor. For instance, it is possible that higher circulating levels of endostatin reflect a reduced renal clearance of endostatin. 56 Moreover, circulating levels of endostatin have been shown to be associated with other important risk factors for mortality such as age, 57 physical activity, [57] [58] [59] body mass index, 60, 61 and glucose intolerance. 60, 61 However, the fact that the results were essentially unaltered in all multivariable models would argue against confounding by these factors as a major explanation of our findings. Still, we cannot rule out confounding by an unmeasured factor.
Clinical Implications
Angiogenesis-modulating treatment of malignant and CVD has gained much interest in the past years, and several of such compounds are now included in the pharmaceutical arsenal. Endostar, 13 an antiangiogenic agent based on endostatin, is currently used in the arsenal treatment against cancer. It should be worthwhile to investigate whether endostatin can be used to monitor such treatment or to identify patients who would benefit from that treatment.
Strengths and Limitations
The strengths of our investigation include the homogenous, community-based study samples with longitudinal data, the detailed characterization of the study participants pertaining to lifestyle and cardiovascular risk factors, and the replication of the results in an independent cohort. To our knowledge, the ULSAM and PIVUS cohorts are the largest cohorts that have analyzed circulating levels of endostatin. Limitations include the unknown generalizability to other age and ethnic groups. 
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